Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05190_nanopub.RAshp9TPUnv40vIBE7hYtKzwfRsPHKEK7OTQ0CihZ04DE#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05190 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05190 label "XL281 [drugbank:DB05190]" assertion.
- drugbank:DB05190 seeAlso DB05190 assertion.
- drugbank:DB05190 description "XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers." assertion.
- drugbank:DB05190 identifier "drugbank:DB05190" assertion.
- drugbank:DB05190 title "XL281" assertion.
- drugbank:DB05190 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05190 drugbank_vocabulary:drugbank-id "DB05190" assertion.
- drugbank:DB05190 bio2rdf_vocabulary:x-identifiers.org DB05190 assertion.
- drugbank:DB05190 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05190" assertion.
- drugbank:DB05190 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05190 bio2rdf_vocabulary:identifier "DB05190" assertion.